Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA

Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )

Longest follow-up of patients with early breast cancer shows radiotherapy does...

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R...

Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients...

Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib ( Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA )

A genomic assay may predict long-term prognosis in premenopausal patients with...

Dr Ruth O'Regan - University of Rochester, Rochester, USA

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )

HER2DX confirms the ability of the test to predict long-term survival and...

Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )

The future of precision oncology

Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany

The future of precision oncology ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )

The concept of pan-tumour therapeutics

Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany

The concept of pan-tumour therapeutics ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Charles Gore - Medicines Patent Pool, Geneva, Switzerland

Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )

Intraoperative ultrasound is accurate for guiding breast conservative surgery...

Dr Antonio Esgueva - Clinica Universidad de Navarra, Madrid, Spain,

Intraoperative ultrasound is accurate for guiding breast conservative surgery in non-palpable ductal breast carcinoma ( Dr Antonio Esgueva - Clinica Universidad de Navarra, Madrid, Spain, )

Cloud software for helping build quality assurance in radiotherapy

Prof Richard Sullivan, Dr Philippa Lewis and Dr Thea Johnson

Cloud software for helping build quality assurance in radiotherapy ( Prof Richard Sullivan, Dr Philippa Lewis and Dr Thea Johnson )

UICC / WHO Policy dialogue: Maintaining cancer care in times of conflict and...

Michael Morrissey - European Cancer Organization, Brussels, Belgium

UICC / WHO Policy dialogue: Maintaining cancer care in times of conflict and environmental emergencies ( Michael Morrissey - European Cancer Organization, Brussels, Belgium )

More from ecancer